Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to .45 Billion

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion



Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
The German pharmaceutical-and-agricultural group said the acquisition would complement its drug pipeline and leverage its ophthalmology footprint.

Leave a Reply

Your email address will not be published. Required fields are marked *